Adapting Clinical Development to an MRD-Integrated Treatment Landscape
Time: 9:50 am
day: Day 2 AM
Details:
- Signatera™ MRD testing is transforming cancer care across tumour types in the US, with growing global adoption in clinical trials. Its impact on patient management is an increasingly important consideration for clinical development strategy
- Analyses from Phase 3 studies demonstrated that MRD-based patient selection can reveal treatment benefits not observed in unselected populations. Incorporating MRD may enable more efficient trial designs by enriching for high-risk patients, accelerating event-driven readouts, expanding development into earlier settings, and informing early go/no-go decisions
- Natera supports the integration of MRD into clinical development and offers additional multi-omic and real-world data (RWD) solutions to inform strategy across the drug development lifecycle
